BFM
ITOS

Boothbay Fund Management’s iTeos Therapeutics ITOS Stock Holding History

Boothbay Fund Management’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,279
Closed -$109K – 1621
2025
Q1 		$109K Hold
18,279
– – ﹤0.01% 1223
2024
Q4 		$140K Sell
18,279
-10,189
-36% -$87.5K ﹤0.01% 1242
2024
Q3 		$291K Buy
28,468
+10,200
+56% +$156K 0.01% 1267
2024
Q2 		$271K Sell
18,268
-5,289
-22% -$75.8K 0.01% 1185
2024
Q1 		$321K Sell
23,557
-52,142
-69% -$568K 0.01% 1173
2023
Q4 		$829K Buy
75,699
+1,720
+2% +$17.1K 0.02% 790
2023
Q3 		$810K Sell
73,979
-1,521
-2% -$19.4K 0.02% 851
2023
Q2 		$1,000K Buy
75,500
+39,848
+112% +$568K 0.02% 831
2023
Q1 		$485K Buy
+35,652
New +$639K 0.01% 1268
2021
Q4 		– Sell
-9,888
Closed -$267K – 2034
2021
Q3 		$267K Buy
9,888
+778
+9% +$20.3K 0.01% 1392
2021
Q2 		$234K Buy
+9,110
New +$217K 0.01% 1426

Other funds holding ITOS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Boothbay Fund Management's ITOS Position: Q2 2025 in Review

Boothbay Fund Management sold out of iTeos Therapeutics (ITOS) in Q2 2025, closing a stake of 18,279 shares — an estimated $109K sold.

Boothbay Fund Management first reported a position in ITOS in Q2 2021 and held it in 11 quarters. The position peaked at $1,000K in Q2 2023. 136 funds tracked by Wall St. Rank hold ITOS as of Q2 2025.

  • Boothbay Fund Management reported no remaining iTeos Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 18,279 iTeos Therapeutics shares in Q2 2025, an estimated $109K.
  • Boothbay Fund Management first reported a position in iTeos Therapeutics in Q2 2021 and held it in 11 quarters.
  • Boothbay Fund Management's iTeos Therapeutics position peaked at $1,000K in Q2 2023.
  • 136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2025.

Based on Boothbay Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.